Evolving BRS technology

Session comprising selected EuroPCR 2017 late-breaking trial submissions

Chairpersons: E. Edelman, Y. Onuma
Panellists: P. Commeau, S. James

Presentations available when logged in:

  • Short and midterm safety, clinical performance and multi modality imaging results of the drug-eluting absorbable metal scaffold: combined data of t...
  • Nine-month clinical and imaging outcomes of a novel ultra-high molecular weight poly-L-lactide BRS. A prospective multicenter international investi...
  • Multicentre evaluation of a novel 120µm DeSolve CX BRS: first report of six-month clinical and imaging endpoints
  • Prospective, multicentre evaluation of the DESolve Novolimus-Eluting coronary BRS: imaging outcomes and four-year clinical and imaging results
  • The FANTOM II study: first report for the 12-month clinical outcomes of the Fantom sirolimus eluting bioresorbable scaffold
  • One-year clinical and multi-slice computed tomography results with a thin-strut poly-L-lactic acid based sirolimus eluting BRS in patients with cor...
  • A first-in-man study of the Firesorb sirolimus target eluting BRS in patients with coronary artery disease (FUTURE-I): one-year clinical and imagin...